April 25th 2024
A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.
Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care
1.0 Credit / Hematology, Oncology
View More
Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
1.0 Credit / Hematology, Oncology
View More
Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions
1.0 Credit / Oncology
View More
Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
1.0 Credit / Hematology, Oncology
View More
Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
1.0 Credit / Hematology, Oncology
View More
Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure
1.0 Credit / Oncology
View More
Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies
1.5 Credits / Oncology
View More
Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions
1.0 Credit / Oncology, Women’s Health
View More
Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure
1.0 Credit / Oncology
View More
Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies
1.0 Credit / Oncology
View More
Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation
1.25 Credit(s) / Oncology; Women’s Health
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Advanced Renal Cell Carcinoma
1.0 Credit / Oncology
View More
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
View More
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
View More
The Impact of Antibody-Drug Conjugates in Bladder Cancer and Gynecologic Malignancies
1.0 Credit / Oncology
View More
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
View More
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
View More
Exploring the Value of Pharmacist-Led Toxicity Management for New and Emerging Antibody-Drug Conjugates Across Solid Tumors
1.25 Credits / Oncology
View More
Improving Patient Outcomes in TNBC: Immunotherapy, PARP, TROP2, Oh My!
2.0 Credits / Oncology
View More
CVD Risk in Type 2 Diabetes May Be Impacted by GnRH Agonists for Prostate Cancer
August 10th 2022New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
Ensuring Equitable Access to Therapeutic Advances in Oncology
February 14th 2022Jenny Sherak, president of Specialty Physician Services at AmerisourceBergen sat down with Drug Topics® to discuss how her team provides the best customer experiences for community oncology practices across the United States.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
Priority Review Granted to Toripalimab by FDA for Nasopharyngeal Carcinoma
November 2nd 2021The FDA has accepted for review a biologics license application for the use of toripalimab in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
Mosunetuzumab Evokes Strong Response in Elderly Population With DLBCL
August 26th 2021Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.
Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma
August 19th 2021An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.